ESR1 and neoplasm: According to IHC analyses, 49.9% (249) of subjects were ER/PR+, HER2-, and tumor grade 1–2, 17.8% (89) were ER/PR+, HER2-, and tumor grade 3; and 30.5% (152) were ER/PR+ and HER2+.